Report Sections

See All Reports

  • HP:0002037: Inflammation of the large intestine
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002037: Inflammation of the large intestine

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (8)


    Name (Synonyms) Correlation
    drug2175 No intervention (survey study for medical doctors). Wiki 0.38
    drug683 Cannabis, Medical Wiki 0.38
    drug2600 Probiotic Wiki 0.22
    Name (Synonyms) Correlation
    drug376 BNT162b1 Wiki 0.22
    drug377 BNT162b2 Wiki 0.19
    drug1671 Interview Wiki 0.19
    drug849 Control Wiki 0.12
    drug2448 Placebo Wiki 0.02

    Correlated MeSH Terms (30)


    Name (Synonyms) Correlation
    D015212 Inflammatory Bowel Diseases NIH 1.00
    D007410 Intestinal Diseases NIH 0.53
    D000070627 Chronic Traumatic Encephalopathy NIH 0.38
    Name (Synonyms) Correlation
    D003092 Colitis NIH 0.38
    D003093 Colitis, Ulcerative NIH 0.38
    D005879 Tourette Syndrome NIH 0.38
    D003424 Crohn Disease NIH 0.38
    D005356 Fibromyalgia NIH 0.27
    D000070642 Brain Injuries, Traumatic NIH 0.27
    D000690 Amyotrophic Lateral Sclerosis NIH 0.27
    D012640 Seizures NIH 0.27
    D016472 Motor Neuron Disease NIH 0.27
    D006526 Hepatitis C NIH 0.27
    D001714 Bipolar Disorder NIH 0.27
    D000755 Anemia, Sickle Cell NIH 0.19
    D001930 Brain Injuries, NIH 0.17
    D001927 Brain Diseases NIH 0.17
    D010300 Parkinsonian NIH 0.15
    D009103 Multiple Sclerosis NIH 0.14
    D012598 Scoliosi NIH 0.13
    D059350 Chronic Pain NIH 0.13
    D004194 Disease NIH 0.08
    D040921 Stress Disorders, Traumatic NIH 0.08
    D013313 Stress Disorders, Post-Traumatic NIH 0.07
    D014947 Wounds and Injuries NIH 0.07
    D013577 Syndrome NIH 0.04
    D045169 Severe Acute Respiratory Syndrome NIH 0.03
    D003141 Communicable Diseases NIH 0.03
    D018352 Coronavirus Infections NIH 0.03
    D007239 Infection NIH 0.02

    Correlated HPO Terms (10)


    Name (Synonyms) Correlation
    HP:0002242 Abnormal intestine morphology HPO 0.53
    HP:0002583 Colitis HPO 0.38
    HP:0100279 Ulcerative colitis HPO 0.38
    Name (Synonyms) Correlation
    HP:0100280 Crohn's disease HPO 0.38
    HP:0006802 Abnormal anterior horn cell morphology HPO 0.27
    HP:0100754 Mania HPO 0.27
    HP:0007354 Amyotrophic lateral sclerosis HPO 0.27
    HP:0001250 Seizure HPO 0.22
    HP:0001298 Encephalopathy HPO 0.17
    HP:0012532 Chronic pain HPO 0.13

    Clinical Trials

    Navigate: Correlations   HPO

    There are 7 clinical trials


    1 Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19

    This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

    NCT03944447
    Conditions
    1. Chronic Pain
    2. Chronic Pain Syndrome
    3. Chronic Pain Due to Injury
    4. Chronic Pain Due to Trauma
    5. Fibromyalgia
    6. Seizures
    7. Hepatitis C
    8. Cancer
    9. Crohn Disease
    10. HIV/AIDS
    11. Multiple Sclerosis
    12. Traumatic Brain Injury
    13. Sickle Cell Disease
    14. Post Traumatic Stress Disorder
    15. Tourette Syndrome
    16. Ulcerative Colitis
    17. Glaucoma
    18. Epilepsy
    19. Inflammatory Bowel Diseases
    20. Parkinson Disease
    21. Amyotrophic Lateral Sclerosis
    22. Chronic Traumatic Encephalopathy
    23. Anxiety
    24. Depression
    25. Insomnia
    26. Autism
    27. Opioid-use Disorder
    28. Bipolar Disorder
    29. Covid19
    30. SARS-CoV Infection
    31. COVID-19
    32. Corona Virus Infection
    33. Coronavirus
    Interventions
    1. Drug: Cannabis, Medical
    MeSH:Infection Communicable Diseases Hepatitis C Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkin Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Wounds and Injuries Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic
    HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

    Primary Outcomes

    Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).

    Measure: Prevention of COVID-19

    Time: Five years

    Description: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).

    Measure: Treatment of COVID-19

    Time: Five years

    Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

    Measure: Treatment of Symptoms

    Time: Five years

    Secondary Outcomes

    Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

    Measure: Cannabis Impact on Quality of Life

    Time: Five years

    Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

    Measure: Cannabis Route and Dosing

    Time: Five years

    Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

    Measure: Monitoring Adverse Events

    Time: Five years
    2 Prospective Multicenter Cohort of Patients With Inflammatory Bowel Disease Treated by Infliximab or Vedolizumab During COVID-19 Pandemic

    Multicenter cohort of patients followed for 6 months during the pandemic in France with biocollection of sera and peripheral blood mononuclear cells

    NCT04344249
    Conditions
    1. IBD
    2. COVID
    MeSH:Inflammatory Bowel Diseases
    HPO:Inflammation of the large intestine

    Primary Outcomes

    Description: Impact of antibodies du to immunosuppressive protocol on the risk of viral infection

    Measure: IgG and IgM anti SARS-CoV-2

    Time: through study completion, an average of 2 year

    Secondary Outcomes

    Description: Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. weight (Kg) height (m) ABO Group ....

    Measure: Clinical factors and severity of COVID-19 infection

    Time: through study completion, an average of 2 year

    Description: Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. ACCOMMODATION HOUSING AREA number of people at home ....

    Measure: demographic factors and severity of COVID-19 infection

    Time: through study completion, an average of 2 year

    Description: Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.

    Measure: pharmacologic factors and severity of COVID-19 infection

    Time: through study completion, an average of 2 year
    3 The Effect of Patient's Perceptions for COVID-19 on the Inflammatory Bowel Disease-related Healthcare Utilization in the Hyperepidemic Area

    The rapid spread of COVID-19 is expected to have a significant impact on medicine as well as all sectors worldwide. In particular, inflammatory bowel disease (IBD) is a chronic immune disease in which remission and activation are repeated and must be treated consistently throughout life. In addition, patients with IBD may be vulnerable to various infectious diseases due to the immuno-compromised state due to the use of immuno-suppressants or biological agents. During a pandemic, patients with IBD may postpone hospital visits due to concerns about infection with COVID-19, and if they cannot continue drug treatment, there is a concern about the flare up IBD disease activity. Therefore, in this study, we would like to investigate the current status of hospital utilization of IBD patients in Daegu, the epidemic area of COVID-19, and to investigate the effect of patient perception of COVID-19 on hospital ultilization.

    NCT04387279
    Conditions
    1. COVID-19
    2. Perception, Self
    3. Facilities and Services Utilization
    Interventions
    1. Other: Interview
    MeSH:Inflammatory Bowel Diseases
    HPO:Inflammation of the large intestine

    Primary Outcomes

    Description: Correlation between patient's perception of COVID-19 and medical use patterns during the pandemic period

    Measure: Patient's perception of COVID-19 and medical use patterns

    Time: 1day

    Secondary Outcomes

    Description: Exacerbation of symptoms in patients with IBD during the pandemic period

    Measure: Exacerbation of symptoms

    Time: 1day
    4 PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic

    To find out what adaptations have been made by Inflammatory bowel disease physicians and patients in relation to therapies in flaring IBD patients during severe acute respiratory syndrome 2-COV and what the impact of these is on IBD patients with no symptomatic COVID-19 and in suspected/confirmed COVID-19. Also whether there any IBD related factors impacting the outcome of patients with COVID-19 symptoms or COVID-19 disease

    NCT04410484
    Conditions
    1. Inflammatory Bowel Diseases
    2. Coronavirus Infection
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Intestinal Diseases Inflammatory Bowel Diseases
    HPO:Abnormal intestine morphology Inflammation of the large intestine

    Primary Outcomes

    Measure: Flare of IBD needing change in therapy or surgery

    Time: 3 months
    5 PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis: A Multi-centre Observational Case- Control Study

    Whether the perceived changes in management of Acute Severe Ulcerative Colitis during the COVID pandemic are widespread, and whether they have any impact on patient outcomes

    NCT04411784
    Conditions
    1. Inflammatory Bowel Diseases
    2. COVID
    MeSH:Colitis Colitis, Ulcerative Inflammatory Bowel Diseases
    HPO:Colitis Inflammation of the large intestine Ulcerative colitis

    Primary Outcomes

    Description: The need for in-hospital colectomy or rescue therapy

    Measure: Primary outcome measure: The need for in-hospital colectomy or rescue therapy

    Time: 3 months

    Secondary Outcomes

    Description: Duration and type/route of steroid use

    Measure: 2.1: Duration and type/route of steroid use

    Time: 3 months

    Description: 30 day colectomy free survival rates

    Measure: 2.2: 30 day colectomy free survival rates

    Time: 3 months

    Description: Covid-19 infection rates

    Measure: 2.3: Covid-19 infection rates

    Time: 3 months

    Description: Rate of Rescue therapy use

    Measure: 2.4: Rate of Rescue therapy use

    Time: 3 months

    Description: Duration of hospital stay

    Measure: 2.5: Duration of hospital stay

    Time: 3 months

    Description: Admission severity scoring

    Measure: 2.6: Admission severity scoring

    Time: 3 months

    Description: Readmission rates

    Measure: 2.7: Readmission rates

    Time: 3 months
    6 Impact of Isolation in Patients With IBD During the 2020 COVID-19 Crisis: a Mixed Methods Study

    The coronavirus pandemic has changed healthcare dramatically in a short time. Individuals with chronic illnesses and services for them have had to adapt and change to deal with requirements for shielding and social isolation to reduce infection risk and management of medication investigation and ongoing review. It is increasingly recognised that the pandemic and the changes to daily life will have had a series of impacts on patients and health care services, including impacts on patients psychological well-being and the opportunity to seek medical care for non-CoViD illness. Psychological symptoms such as depression, anxiety and hopelessness is well described in adults and young people with inflammatory bowel disease. Quarantine has also been associated with these psychological symptoms and also post-traumatic stress. It is important to identify the extent of and factors that influence negative psychological consequences of isolation in patients with inflammatory bowel disease. This study will aim to assess what impact the isolation of patients during social isolation had in terms of psychological well-being - and what are the factors affecting this impact, particularly in younger and old age groups.

    NCT04488471
    Conditions
    1. Inflammatory Bowel Diseases
    MeSH:Inflammatory Bowel Diseases
    HPO:Inflammation of the large intestine

    Primary Outcomes

    Description: Psychological morbidity will be assessed through the 4 questionnaires

    Measure: What impact has the isolation of patients during social isolation had in terms of psychological morbidity?

    Time: Changes in psychological morbidity at 12 months

    Secondary Outcomes

    Description: psychological morbidity will be assessed via comparison of questionnaires from affiliated study against the time points of this study

    Measure: Have levels of psychological morbidity in young people changed from levels prior to the CoViD pandemic?

    Time: Changes in psychological morbidity at 12 months
    7 SARS-CoV-2 Infection in Patients From Two Tertiary Inflammatory Bowel Disease (IBD) Centres: Frequency of Suspected and Confirmed Infections, Severity and Outcome Management

    Most of the inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) in a tertiary expert Centre are on immunosuppressive and/or biological therapy. Theoretically, these treatments may increase patients' risk of infection, in particular viral infection. Therefore, the current SARS-Cov-2 pandemia, with its unprecedent worldwide morbidity and mortality, may have a negative impact on IBD patients' clinical course. Identifying an increased risk in this particular patients' population as well as the risk/protective factors is of outstanding importance, in order to adapt their treatment and surveillance. As a consequence, our aims were (i) to measure retrospectively the risk of SARS-CoV-2 (proven by biological testing or suspected due to record of potential clinical symptoms of COVID-19 infection) in this patients' cohort (principal objective), (ii) to identify risk or protective factors for SARS-CoV-2 infection in IBD, and (iii) to analyze the outcome of patients in case of suspected or confirmed COVID-19. The results of this study may be important to adjust our surveillance and therapeutic strategy in these patients, in particular if high virus circulation will occur in the future.

    NCT04492267
    Conditions
    1. Inflammatory Bowel Disease
    MeSH:Intestinal Diseases Inflammatory Bowel Diseases
    HPO:Abnormal intestine morphology Inflammation of the large intestine

    Primary Outcomes

    Measure: Retrospective analysis of severity and specific needs in case of SARS-CoV-2 infection in IBD patients

    Time: Files analysed retrospectily from March 1st, 2020 to July 31, 2020 will be examined

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook